Brief: Titan Pharmaceuticals Says On April 5 Got Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
11/04/2023 22:01
April 11 (Reuters) - Titan Pharmaceuticals Inc TTNP.O :
* TITAN PHARMACEUTICALS-ON APRIL 5 GOT NOTICE OF DELISTING
OR
FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD; TRANSFER
OF LISTING FROM NASDAQ
Source text for Eikon: ID:
Further company coverage: TTNP.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Titan Pharmaceuticals
See all newsBrief: Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock
Brief: Titan Pharmaceuticals- Appoints Brynner Chiam As Acting Principal Executive Officer & Acting Principal Financial Officer Of Co
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group
Titan Pharma falls as CEO announces resignation
Brief: Titan Pharmaceuticals Enters Into Merger Agreement With Ke Sdn. Bhd.